Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
Cash Generation ExpandingExpanding
Percentile Rank86
Studio
Year-over-Year Change

Cash generated from core business operations

Percentile
P86
Within normal range
vs 3Y Ago
-17.9x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$-18.92M+18.1%
2024$-23.09M+19.2%
2023$-28.57M-2797.5%
2022$1.06M+104.5%
2021$-23.56M-19.3%
2020$-19.75M+38.2%
2019$-31.95M-3.4%
2018$-30.88M-1.2%
2017$-30.52M+27.9%
2016$-42.33M-